<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.cmjournal.org/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Chinese Medicine - Most accessed articles</title>
        <link>http://www.cmjournal.org</link>
        <description>The most accessed research articles published by Chinese Medicine</description>
        <dc:date>2009-06-12T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/4/1/11" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/4/1/10" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/4/1/9" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/4/1/8" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/4/1/7" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/2/1/6" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/11" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/4/1/4" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/1/1/4" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/7" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.cmjournal.org/content/4/1/11">
        <title>Hypoglycemic herbs and their action mechanisms</title>
        <description>Conventional drugs treat diabetes by improving insulin sensitivity, increasing insulin production and/or decreasing the amount of glucose in blood. Several herbal preparations are used to treat diabetes, but their reported hypoglycemic effects are complex or even paradoxical in some cases. This article reviews recent findings about some of the most popular hypoglycemic herbs, such as ginseng, bitter melon and Coptis chinensis. Several popular commercially available herbal preparations are also discussed, including ADHF (anti-diabetes herbal formulation), Jiangtangkeli, YGD (Yerbe Mate-Guarana-Damiana) and BN (Byakko-ka-ninjin-to). The efficacy of hypoglycemic herbs is achieved by increasing insulin secretion, enhancing glucose uptake by adipose and muscle tissues, inhibiting glucose absorption from intestine and inhibiting glucose production from heptocytes.</description>
        <link>http://www.cmjournal.org/content/4/1/11</link>
                <dc:creator>Hongxiang Hui</dc:creator>
                <dc:creator>George Tang</dc:creator>
                <dc:creator>Vay Liang Go</dc:creator>
                <dc:source>Chinese Medicine 2009, 4:11</dc:source>
        <dc:date>2009-06-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-4-11</dc:identifier>
        <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2009-06-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/4/1/10">
        <title>Probing the mystery of Chinese medicine meridian channels with special emphasis on the connective tissue interstitial fluid system, mechanotransduction, cells durotaxis and mast cell degranulation</title>
        <description>This article hypothesizes that the Chinese medicine meridian system is a special channel network comprising of skin with abundant nerves and nociceptive receptors of various types, and deeper connective tissues inside the body with the flowing interstitial fluid system. These meridian channels provide efficient migratory tracks mainly due to durotaxis (also including chemotaxis) for mast cells, fibroblasts and other cells to migrate and carry out a number of physiological functions. Acupuncture acting on meridian channel causes cytoskeletal remodeling through mechanotransduction, leading to regulation of gene expression and the subsequent production of related proteins. Also, stimulation on cell surface can trigger Ca2+ activities, resulting in a cascade of intra- and inter-cellular signaling. Moreover, nerve endings in the meridian channels interact with mast cells and induce the degranulation of these cells, leading to the release of many specific biomolecules needed for homeostasis, immune surveillance, wound healing and tissue repair. Acupoint along a meridian channel is a functional site to trigger the above functions with specificity and high efficiency.</description>
        <link>http://www.cmjournal.org/content/4/1/10</link>
                <dc:creator>Peter Chin Wan Fung</dc:creator>
                <dc:source>Chinese Medicine 2009, 4:10</dc:source>
        <dc:date>2009-05-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-4-10</dc:identifier>
        <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2009-05-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/4/1/9">
        <title>Evaluation of Applied Kinesiology meridian techniques by means of surface electromyography (sEMG): demonstration of the regulatory influence of antique acupuncture points</title>
        <description>Background:
The use of Applied Kinesiology techniques based on manual muscle tests relies on the relationship between muscles and acupuncture meridians. Applied Kinesiology detects body dysfunctions based on changes in muscle tone. Muscle tonification or inhibition within the test setting can be achieved with selected acupoints. These acupoints belong to either the same meridian or related meridians. The aim of this study is to analyze muscle sedation and tonification by means of surface electromyography.
Methods:
Manual muscle tests were carried out using standard Applied Kinesiology (AK) techniques. The investigation included basic AK procedures such as sedation and tonification with specific acupoints. The sedation and tonification acupoints were selected from related meridians according to the Five Elements. The tonification effect of these acupoints was also tested while interfering effects were induced by manual stimulation of scars. The effects of selective neural therapy, i.e. individually tested and selected anesthetic agent, for the treatment of scars were also studied. The characteristics of muscle action were documented by surface electromyographys (sEMG).
Results:
The sEMG data showed a diminution of signal intensity when sedation was used. Graded sedation resulted in a graded diminution of signal amplitude. Graded increase in signal amplitude was observed when antique acupuncture points were used for tonification. The tactile stretch stimulus of scars localized in meridian-independent places produced diminution of signal intensity on a reference muscle, similar to sedation. These changes, however, were not corrected by tonification acupoints. Correction of these interferences was achieved by lesion specific neural therapy with local anesthetics.
Conclusion:
We demonstrated the central working principles, i.e. sedation and tonification, of Applied Kinesiology through the use of specific acupoints that have an influence on manual muscle tests. Sedation decreases RMS signal in sEMG, whereas tonification increases it. Interfering stimuli from scars were corrected by selective neural therapy.</description>
        <link>http://www.cmjournal.org/content/4/1/9</link>
                <dc:creator>Roy Moncayo</dc:creator>
                <dc:creator>Helga Moncayo</dc:creator>
                <dc:source>Chinese Medicine 2009, 4:9</dc:source>
        <dc:date>2009-05-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-4-9</dc:identifier>
        <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2009-05-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/4/1/8">
        <title>Further validation of the Health Scale of Traditional Chinese Medicine (HSTCM)</title>
        <description>Background:
Few health measurement scales are based on Chinese medicine theory. The Health Scale of Traditional Chinese Medicine (HSTCM) was developed to fill this gap. The aim of this study is to validate the HSTCM.
Methods:
A convenience sample of 630 participants was recruited in 11 settings. All participants were asked to complete the HSTCM and World Health Organization Quality of Life Measure-Abbreviated Version (WHOQOL-BREF).
Results:
Properties of the HSTCM were tested. Intra-class correlation coefficient representing the inter-interviewer reliability was 0.99 (95%CI) for the overall instrument. Spearman-Brown correlation coefficient and Cronbach&apos;s coefficient alpha were 0.81 and 0.94 respectively, indicating satisfactory internal reliability and inter-interviewer reliability. Spearman&apos;s rho correlation coefficient between the HSTCM and WHOQOL-BREFF was -0.67. A receiver operating characteristic (ROC) curve analysis was performed to test the discriminate validation. Areas under the ROC curve analysis for the HSTCM and its domains ranged 0.71&#8211;0.87 and all the lower levels of 95%CI were greater than 0.50.
Conclusion:
The HSTCM was validated as a generic health scale and may complement existing health measurement scales in Chinese medicine health care.</description>
        <link>http://www.cmjournal.org/content/4/1/8</link>
                <dc:creator>Darong Wu</dc:creator>
                <dc:creator>Shilong Lai</dc:creator>
                <dc:creator>Luojing Zhou</dc:creator>
                <dc:creator>Xinfeng Guo</dc:creator>
                <dc:creator>Weixiong Liang</dc:creator>
                <dc:creator>Zehuai Wen</dc:creator>
                <dc:creator>Aihua Ou</dc:creator>
                <dc:creator>Guangqing Zhang</dc:creator>
                <dc:creator>Keji Chen</dc:creator>
                <dc:source>Chinese Medicine 2009, 4:8</dc:source>
        <dc:date>2009-04-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-4-8</dc:identifier>
        <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2009-04-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/4/1/7">
        <title>Recent developments of acupuncture in Australia and the way forward</title>
        <description>Almost one in ten Australians has received acupuncture treatment by acupuncturists and/or medical doctors in private clinics. The majority of Australian health insurance funds offer rebates for acupuncture. Statutory regulations for acupuncture have been implemented in the State of Victoria, Australia. Six acupuncture degree courses have been approved by the Chinese Medicine Registration Board of Victoria and/or accredited by the Australian Acupuncture and Chinese Medicine Association. Furthermore, a number of clinical trials of acupuncture on allergic rhinitis, pain and women&apos;s health were carried out in Australia. Recent developments of acupuncture in Australia indicate that through adequate and appropriate evaluation, acupuncture begins to integrate into mainstream health care in Australia.</description>
        <link>http://www.cmjournal.org/content/4/1/7</link>
                <dc:creator>Charlie Xue</dc:creator>
                <dc:creator>Anthony Zhang</dc:creator>
                <dc:creator>Angela Yang</dc:creator>
                <dc:creator>Shuiqing Zhang</dc:creator>
                <dc:creator>David Story</dc:creator>
                <dc:source>Chinese Medicine 2009, 4:7</dc:source>
        <dc:date>2009-04-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-4-7</dc:identifier>
        <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2009-04-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/2/1/6">
        <title>Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides</title>
        <description>In Chinese medicine, ginseng (Panax ginseng C.A. Meyer) has long been used as a general tonic or an adaptogen to promote longevity and enhance bodily functions. It has also been claimed to be effective in combating stress, fatigue, oxidants, cancer and diabetes mellitus. Most of the pharmacological actions of ginseng are attributed to one type of its constituents, namely the ginsenosides. In this review, we focus on the recent advances in the study of ginsenosides on angiogenesis which is related to many pathological conditions including tumor progression and cardiovascular dysfunctions.Angiogenesis in the human body is regulated by two sets of counteracting factors, angiogenic stimulators and inhibitors. The &apos;Yin and Yang&apos; action of ginseng on angiomodulation was paralleled by the experimental data showing angiogenesis was indeed related to the compositional ratio between ginsenosides Rg1 and Rb1. Rg1 was later found to stimulate angiogenesis through augmenting the production of nitric oxide (NO) and vascular endothelial growth factor (VEGF). Mechanistic studies revealed that such responses were mediated through the PI3K&#8594;Akt pathway. By means of DNA microarray, a group of genes related to cell adhesion, migration and cytoskeleton were found to be up-regulated in endothelial cells. These gene products may interact in a hierarchical cascade pattern to modulate cell architectural dynamics which is concomitant to the observed phenomena in angiogenesis. By contrast, the anti-tumor and anti-angiogenic effects of ginsenosides (e.g. Rg3 and Rh2) have been demonstrated in various models of tumor and endothelial cells, indicating that ginsenosides with opposing activities are present in ginseng. Ginsenosides and Panax ginseng extracts have been shown to exert protective effects on vascular dysfunctions, such as hypertension, atherosclerotic disorders and ischemic injury. Recent work has demonstrates the target molecules of ginsenosides to be a group of nuclear steroid hormone receptors. These lines of evidence support that the interaction between ginsenosides and various nuclear steroid hormone receptors may explain the diverse pharmacological activities of ginseng. These findings may also lead to development of more efficacious ginseng-derived therapeutics for angiogenesis-related diseases.</description>
        <link>http://www.cmjournal.org/content/2/1/6</link>
                <dc:creator>Patrick Ying Kit Yue</dc:creator>
                <dc:creator>Nai Ki Mak</dc:creator>
                <dc:creator>Yuen Kit Cheng</dc:creator>
                <dc:creator>Kar Wah Leung</dc:creator>
                <dc:creator>Tzi Bun Ng</dc:creator>
                <dc:creator>David Tai Ping Fan</dc:creator>
                <dc:creator>Hin Wing Yeung</dc:creator>
                <dc:creator>Ricky Ngok Shun Wong</dc:creator>
                <dc:source>Chinese Medicine 2007, 2:6</dc:source>
        <dc:date>2007-05-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-2-6</dc:identifier>
        <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2007-05-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/3/1/11">
        <title>Recent advances in the investigation of curcuminoids</title>
        <description>More than 30 Curcuma species (Zingiberaceae) are found in Asia, where the rhizomes of these plants are used as both food and medicine, such as in traditional Chinese medicine. The plants are usually aromatic and carminative, and are used to treat indigestion, hepatitis, jaundice, diabetes, atherosclerosis and bacterial infections. Among the Curcuma species, C. longa, C. aromatica and C. xanthorrhiza are popular. The main constituents of Curcuma species are curcuminoids and bisabolane-type sesquiterpenes. Curcumin is the most important constituent among natural curcuminoids found in these plants. Published research has described the biological effects and chemistry of curcumin. Curcumin derivatives have been evaluated for bioactivity and structure-activity relationships (SAR). In this article, we review the literature between 1976 and mid-2008 on the anti-inflammatory, anti-oxidant, anti-HIV, chemopreventive and anti-prostate cancer effects of curcuminoids. Recent studies on curcuminoids, particularly on curcumin, have discovered not only much on the therapeutic activities, but also on mechanisms of molecular biological action and major genomic effects.</description>
        <link>http://www.cmjournal.org/content/3/1/11</link>
                <dc:creator>Hideji Itokawa</dc:creator>
                <dc:creator>Qian Shi</dc:creator>
                <dc:creator>Toshiyuki Akiyama</dc:creator>
                <dc:creator>Susan Morris-Natschke</dc:creator>
                <dc:creator>Kuo-Hsiung Lee</dc:creator>
                <dc:source>Chinese Medicine 2008, 3:11</dc:source>
        <dc:date>2008-09-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-3-11</dc:identifier>
        <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>3</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2008-09-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/4/1/4">
        <title>Moxibustion and other acupuncture point stimulation methods to treat breech presentation: a systematic review of clinical trials</title>
        <description>Background:
Moxibustion, acupuncture and other acupoint stimulations are commonly used for the correction of breech presentation. This systematic review aims to evaluate the efficacy and safety of moxibustion and other acupoint stimulations to treat breech presentation.
Methods:
We included randomized controlled trials (RCTs) and controlled clinical trials (CCTs) on moxibustion, acupuncture or any other acupoint stimulating methods for breech presentation in pregnant women. All searches in PubMed, the Cochrane Library (2008 Issue 2), China National Knowledge Information (CNKI), Chinese Scientific Journal Database (VIP) and WanFang Database ended in July 2008. Two authors extracted and analyzed the data independently.
Results:
Ten RCTs involving 2090 participants and seven CCTs involving 1409 participants were included in the present study. Meta-analysis showed significant differences between moxibustion and no treatment (RR 1.35, 95% CI 1.20 to 1.51; 3 RCTs). Comparison between moxibustion and knee-chest position did not show significant differences (RR 1.30, 95% CI 0.95 to 1.79; 3 RCTs). Moxibustion plus other therapeutic methods showed significant beneficial effects (RR 1.36, 95% CI 1.21 to 1.54; 2 RCTs). Laser stimulation was more effective than assuming the knee-chest position plus pelvis rotating. Moxibustion was more effective than no treatment (RR 1.29, 95% CI 1.17 to 1.42; 2 CCTs) but was not more effective than the knee-chest position treatment (RR 1.22, 95% CI 1.11 to 1.34; 2 CCTs). Laser stimulation at Zhiyin (BL67) was more effective than the knee-chest position treatment (RR 1.30, 95% CI 1.10 to 1.54; 2 CCTs,).
Conclusion:
Moxibustion, acupuncture and laser acupoint stimulation tend to be effective in the correction of breech presentation.</description>
        <link>http://www.cmjournal.org/content/4/1/4</link>
                <dc:creator>Xun Li</dc:creator>
                <dc:creator>Jun Hu</dc:creator>
                <dc:creator>Xiaoyi Wang</dc:creator>
                <dc:creator>Huiri Zhang</dc:creator>
                <dc:creator>Jianping Liu</dc:creator>
                <dc:source>Chinese Medicine 2009, 4:4</dc:source>
        <dc:date>2009-02-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-4-4</dc:identifier>
        <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2009-02-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/1/1/4">
        <title>Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials</title>
        <description>Extracts of Chinese red yeast rice (RYR, a traditional dietary seasoning of Monascus purpureus) contains several active ingredients including lovastatin, and several trials of its possible lipid-lowering effects have been conducted. This meta-analysis assesses the effectiveness and safety of RYR preparations on lipid modification in primary hyperlipidemia. We included randomized controlled trials testing RYR preparation, compared with placebo, no treatment, statins, or other active lipid-lowering agents in people with hyperlipidemia through searching PubMed, CBMdisk, TCMLARS, the Cochrane Library, and AMED up to December 2004. Ninety-three randomized trials (9625 participants) were included and three RYR preparations (Cholestin, Xuezhikang and Zhibituo) were tested. The methodological quality of trial reports was generally low in terms of generation of the allocation sequence, allocation concealment, blinding, and intention-to-treat. The combined results showed significant reduction of serum total cholesterol levels (weighted mean difference -0.91 mmol/L, 95% confidence interval -1.12 to -0.71), triglycerides levels (-0.41 mmol/L, -0.6 to -0.22), and LDL-cholesterol levels (-0.73 mmol/L, -1.02 to -0.043), and increase of HDL-cholesterol levels (0.15 mmol/L, 0.09 to 0.22) by RYR treatment compared with placebo. The lipid modification effects appeared to be similar to pravastatin, simvastatin, lovastatin, atorvastatin, or fluvastatin. Compared with non-statin lipid lowering agents, RYR preparations appeared superior to nicotinate and fish oils, but equal to or less effective than fenofibrate and gemfibrozil. No significant difference in lipid profile was found between Xuezhikang and Zhibituo. RYR preparations were associated with non-serious adverse effects such as dizziness and gastrointestinal discomfort. Current evidence shows short-term beneficial effects of RYR preparations on lipid modification. More rigorous trials are needed, and long-term effects and safety should be investigated if RYR preparations are to be recommended as one of the alternative treatments for primary hyperlipidemia.</description>
        <link>http://www.cmjournal.org/content/1/1/4</link>
                <dc:creator>Jianping Liu</dc:creator>
                <dc:creator>Jing Zhang</dc:creator>
                <dc:creator>Yi Shi</dc:creator>
                <dc:creator>Sameline Grimsgaard</dc:creator>
                <dc:creator>Terje Alraek</dc:creator>
                <dc:creator>Vinjar Fonnebo</dc:creator>
                <dc:source>Chinese Medicine 2006, 1:4</dc:source>
        <dc:date>2006-11-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-1-4</dc:identifier>
        <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>1</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2006-11-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/3/1/7">
        <title>Chemical markers for the quality control of herbal medicines: an overview</title>
        <description>Selection of chemical markers is crucial for the quality control of herbal medicines, including authentication of genuine species, harvesting the best quality raw materials, evaluation of post-harvesting handling, assessment of intermediates and finished products, and detection of harmful or toxic ingredients. Ideal chemical markers should be the therapeutic components of herbal medicines. However, for most herbal medicines, the therapeutic components have not been fully elucidated or easily monitored. Bioactive, characteristic, main, synergistic, correlative, toxic and general components may be selected. This article reviews the effective use of chemical markers in the quality control of herbal medicines including the selection criteria considering the roles and physicochemical factors which may affect the effective use of chemical markers.</description>
        <link>http://www.cmjournal.org/content/3/1/7</link>
                <dc:creator>Songlin Li</dc:creator>
                <dc:creator>Quanbin Han</dc:creator>
                <dc:creator>Chunfeng Qiao</dc:creator>
                <dc:creator>Jingzheng Song</dc:creator>
                <dc:creator>Chuen Lung Cheng</dc:creator>
                <dc:creator>Hongxi Xu</dc:creator>
                <dc:source>Chinese Medicine 2008, 3:7</dc:source>
        <dc:date>2008-06-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-3-7</dc:identifier>
        <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>3</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2008-06-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
